InvestSMART

CSL Limited (ASX: CSL) - ETF Exposure

Current share price for CSL : $173.475 4.365 (2.58%)+

CSL (CSL Limited) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology.

CSL General Information +

ASX Code CSL
Website N/A
Industry/Sector Biotechnology
Market Cap ($M) 83,119
CSL Share Price $173.560
Day High $174.750
Day Low $170.320
Last Close $169.110
CSL Share Price Movement $4.45 ( 2.63% )
Prices as at 14:20, 25 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to CSL

As one of Australia's largest companies by market capitalisation, CSL is held across 52 ETFs spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when CSL moves, funds like SYI, OZXX, IMLC, GRNV and IESG that hold it can move with it.

For more concentrated exposure, ETFs such as SYI (SPDR MSCI Australia Select High Dividend Yield Fund) allocate about 11.4% to CSL , while the average exposure across all 52 ETFs that hold it is around 3.4% .

Top ETF holdings

Last updated: ETF data and holdings as at 24 August 2026

Own CSL directly or through an ETF?

How does holding CSL Limited (CSL) shares directly compare to ETFs that include it?

CSL Direct
SYI
ASX 		OZXX
ASX 		IMLC
ASX 		GRNV
ASX 		IESG
ASX
Holdings 1 company 61 holdings 104 holdings 10 holdings 82 holdings 95 holdings
CSL Weight 100% 11.4% 10.6% 9.2% 7.9% 7%
Diversification Single Stock Broad Broad Broad Broad Broad
Annual Cost Brokerage only 0.2% p.a. 0.25% p.a. 0.99% p.a. 0.35% p.a. 0.09% p.a.
Approx. Yield 3.6% 7.21% 5.14% 8.74% 3.51% 2.46%
Star Ratings - starstarstarstar starstar star starstarstarstar starstarstarstar

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not CSL's direct yield. Annual cost uses each ETF's MER.

CSL Exposure on $10,000 investment

How a $10,000 investment in CSL Limited (CSL) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
CSL Limited (CSL) Direct share $173.560 28.95% +$2,895 $12,895
SPDR MSCI Australia Select High Dividend Yield Fund (SYI) Equity - Australia Strategy $31.720 1.90% +$190 $10,190
Global X Australia ex Financials & Resources ETF (OZXX) Equity - Australia Sectors $10.040 -0.10% -$10 $9,990
Investors Mutual Concentrated Australian Share Fund (Quoted Managed Fund) (IMLC) Equity - Australia Strategy $3.840 0% $0 $10,000
VanEck MSCI Australian Sustainable Equity ETF (GRNV) Equity - Australia Strategy $32.720 1.65% +$165 $10,165
iShares Core MSCI Australia ESG Leaders ETF (IESG) Equity - Australia Strategy $32.320 1.80% +$180 $10,180

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

CSL Limited (CSL) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
HFResult $2.28 0% 9 Sep 2026 2 Oct 2026 - - -
Result $1.81 0% 10 Mar 2026 9 Apr 2026 - - -
HFResult $2.45 0% 9 Sep 2025 3 Oct 2025 - - -

See all dividends from CSL Limited (CSL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

CSL Limited (CSL) price-sensitive announcements

CSL - CSL Results Presentation for FY2026
CSL Limited's FY2026 results presentation reports a mixed financial performance characteri
CSL Limited (CSL)
18 Aug 2026 | 8:01 AM
CSL - CSL FY2026 Results
CSL Limited reported a challenging FY2026 with a net loss after tax of US$2.6 billion due
CSL Limited (CSL)
18 Aug 2026 | 8:00 AM
CSL - CSL Statutory Accounts for FY2026
For FY2026, CSL Limited reported a net loss of US$2.579 billion, mainly due to restructuri
CSL Limited (CSL)
18 Aug 2026 | 7:58 AM
CSL - CSL Update on Enhanced Plasma Manufacturing
CSL Limited announced plans to commence clinical trials for its Horizon 2 plasma manufactu
CSL Limited (CSL)
29 Jul 2026 | 9:21 AM

CSL Limited (CSL) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
CSL Limited (CSL)
ORDINARY FULLY PAID
 Health Care $83,120 CSL Appendix 4G and Corporate Governance Statement 18 Aug 2026 8:02AM $134.600 $173.560 risen by 28.95%
CSL Limited (CSL)
ORDINARY FULLY PAID
 Health Care $83,120 CSL Results Presentation for FY2026 18 Aug 2026 8:01AM $134.600 $173.560 risen by 28.95%
CSL Limited (CSL)
ORDINARY FULLY PAID
 Health Care $83,120 Dividend/Distribution - CSL 18 Aug 2026 8:00AM $134.600 $173.560 risen by 28.95%
CSL Limited (CSL)
ORDINARY FULLY PAID
 Health Care $83,120 CSL FY2026 Results 18 Aug 2026 8:00AM $134.600 $173.560 risen by 28.95%
CSL Limited (CSL)
ORDINARY FULLY PAID
 Health Care $83,120 CSL Statutory Accounts for FY2026 18 Aug 2026 7:58AM $134.600 $173.560 risen by 28.95%
CSL Limited (CSL)
ORDINARY FULLY PAID
 Health Care $83,120 Notification of cessation of securities - CSL 6 Aug 2026 8:20AM $130.660 $173.560 risen by 32.83%

CSL Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026F $5,692.27 $1,172.70 14.40% 23.05 516.08 1.91% 0.0%
2025F $4,974.44 $1,024.81 15.10% 26.38 451.14 1.67% 0.0%
2024A $4,318.18 $889.99 11.10% 30.63 392.16 1.44% 0.0%

CSL Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 F 2026 F 2024 A 2025 F 2026 F 2024 A 2025 F 2026 F
CSL Limited (CSL) $80,601M 0.7309 -0.4359 0.0505 10.4265 18.4850 17.5963 2.53% 2.51% 2.59%
Clinuvel Pharmaceuticals Limited (CUV) $525M 0.0287 0.0000 0.0000 14.5125 0.0000 0.0000 0.48% 0.00% 0.00%
Immutep Limited (IMM) $78M 0.1854 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $3,065M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,307M -1.3893 0.0000 -0.8985 0.0000 176.0992 1,735.5556 0.00% 0.00% 0.00%

CSL Directors

Name Position Start Date
Mr Gordon Naylor Chief Executive Officer, Managing Director 1 Dec 2025
Ms Carolyn Judith Hewson Non-Executive Director 9 Dec 2019
Ms Alison Mary Watkins Non-Executive Director 18 Aug 2021
Dr Robert Andrew Cuthbertson Non-Executive Director 17 Oct 2018
Ms Samantha (Sam) Louise Lewis Non-Executive Director 1 Jan 2024
Ms Elaine Sorg Non-Executive Director 1 Sep 2024
Dr Brian Daniels Non-Executive Director 1 Dec 2024
Mr Cameron Bruce Price Non-Executive Director 1 Oct 2025
Mr Constantine Saroukos Non-Executive Director 1 Dec 2025
Dr Brian Anthony McNamee Non-Executive Director, Non-Executive Chairman 13 Feb 2018

CSL Limited (CSL) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
1 Jun 2026 HEWSON, Carolyn Buy Indirect Shares 1,036 $95.890 $99,342.040
26 May 2026 NAYLOR, Gordon Buy Indirect Shares 1,100 $98.000 $107,800.000
15 May 2026 WATKINS, Alison Buy Indirect Shares 2,540 $98.660 $250,595.380

See all changes in directors' interest & trades for CSL Limited (CSL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CSL Management

Name Position
Ken Lim CFO
Mark Hill Chief Information Officer
Fiona Mead Company Secretary,Head of Group Governance
Kate Priestman Other Corporate Officer
Amy Van Buren Other Corporate Officer
Andy Schmeltz Other Executive Officer
Diego Sacristan Other Executive Officer
Herve Gisserot Vice President, Divisional
Mary Oates Vice President, Divisional
Stephen Marlow Vice President, Divisional
Bill Mezzanotte Vice President, Divisional
David Ross Vice President, Divisional
Greg Boss Vice President, Divisional

CSL Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in CSL Limited (CSL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
39,466,383 (8.13%) State Street Corporation and subsidiaries
33,744,255 (7.04%) BlackRock Group
29,109,134 (6%) The Vanguard Group,Inc

CSL Calendar of Events

Date Event
17 August 2027 Report (Annual)
17 August 2027 Report (Prelim)
10 February 2027 Report (Interim)
27 October 2026 AGM
02 October 2026 Div Pay Date
10 September 2026 Books Close
09 September 2026 Div Ex Date

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.